Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

12-11-2019 | Psoriatic arthritis | Video | Article

Expert commentary: The DISCOVER trials

print
PRINT
insite
SEARCH

Oliver FitzGerald comments on the findings from the DISCOVER-1 and DISCOVER-2 trials, which demonstrated the efficacy of guselkumab for the treatment of psoriatic arthritis (3:36).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Transcript

Back to the ACR/ARP 2019 conference hub

print
PRINT

Related content

01-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | Article

Researcher comment: The DISCOVER-2 trial

12-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | News

Guselkumab shows promise for PsA

08-11-2017 | Psoriatic arthritis | ACR/ARHP 2017 | News

Guselkumab efficacy maintained in psoriatic arthritis patients
Image Credits